Tools and resources for advanced NSCLC

For your patients
Non-small cell lung cancer pre-treatment checklist
Preparing for My Treatment
Show your patients items they may want to have on hand before their treatment begins. The list also includes arrangements they may want to make ahead of time so they get the support they may need during treatment with ABRAXANE.
Doctor visit guide for non-small cell lung cancer
Doctor Visit Discussion Guide
Helps your patients talk about treatment with ABRAXANE before treatment begins.
Non-small cell lung cancer questions for my healthcare team
Questions for My Healthcare Team
Lists frequently asked questions about ABRAXANE and provides space for your patients to write down questions.
Treatment tracker for non-small cell lung cancer
Treatment Diary
Helps you stay organized by keeping track of appointments and any symptoms you may experience so that you become more aware of how treatment with ABRAXANE may affect you.
Non-small cell lung cancer patient brochure
Patient Brochure
Helps your patients understand their treatment.

This brochure is also available on:

Interactive Guide Webbook
For healthcare professionals
ABRAXANE dosing app for ipad and android
Celgene Dosing App for ABRAXANE Dosing information for all 3 ABRAXANE indications
Download on the App StoreAndroid App on Google play
Hear from an expert
NSCLC Phase 3 Trial design video
Phase 3 Trial Design Overview of the clinical trial in patients with advanced NSCLC: a comparison of ABRAXANE + carboplatin vs paclitaxel + carboplatin.
NSCLC trial results video
Trial Results Results from the phase 3 clinical trial in patients with advanced NSCLC.
NSCLC safety and tolerability video
Safety and Tolerability Safety and tolerability results from the phase 3 clinical trial in advanced NSCLC.
NSCLC dosing recommendations video
Dosing Recommendations Dosing recommendations and modifications for ABRAXANE + carboplatin.
Download the Prescribing Information for ABRAXANE
ABRAXANE Full Prescribing Information Download the Prescribing Information for ABRAXANE.

Tools and resources for advanced NSCLC

For your patients

Non-small cell lung cancer pre-treatment checklist
Preparing for My Treatment

Show your patients items they may want to have on hand before their treatment begins. The list also includes arrangements they may want to make ahead of time so they get the support they may need during treatment with ABRAXANE.

Doctor visit guide for non-small cell lung cancer
Doctor Visit Discussion Guide

Helps your patients talk about treatment with ABRAXANE before treatment begins.

Non-small cell lung cancer questions for my healthcare team
Questions for My Healthcare Team

Lists frequently asked questions about ABRAXANE and provides space for your patients to write down questions.

Treatment tracker for non-small cell lung cancer
Treatment Diary

Helps you stay organized by keeping track of appointments and any symptoms you may experience so that you become more aware of how treatment with ABRAXANE may affect you.

Non-small cell lung cancer patient brochure
Patient Brochure

Helps your patients understand their treatment. This brochure is also available on:

Interactive Guide Webbook

For healthcare professionals

Download the Prescribing Information for ABRAXANE
ABRAXANE Full Prescribing Information

Download the Prescribing Information for ABRAXANE.

INDICATIONS

ABRAXANE is indicated for:

  • The treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
  • The first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
  • The first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine

INDICATIONS

ABRAXANE is indicated for:

  • The treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
  • The first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
  • The first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine